Patient Leaflet Updated 07-Aug-2025 | Ferring Pharmaceuticals Ltd
Lutigest 100 mg vaginal tablets
Lutigest 100 mg Vaginal tablets
Progesterone
1. What Lutigest is and what it is used for
2. What you need to know before you use Lutigest
3. How to use Lutigest
4. Possible side effects
5. How to store Lutigest
6. Contents of the pack and other information
This medicine is provided as a vaginal tablet that contains the natural female sex hormone progesterone.
Lutigest is for women who need extra progesterone while undergoing treatment in an Assisted Reproductive Technology (ART) programme.
Progesterone acts on the lining of the womb and it helps you to become and to stay pregnant when you are treated for infertility.
Lutigest can be used only in women who are undergoing infertility treatment in an Assisted Reproductive Technology (ART) programme. The treatment is started on the day of egg retrieval. Your doctor will tell you when the treatment is started.
Take special care and tell your doctor straight away if you experience any of these symptoms during treatment or even few days after the last dosage:
Before starting treatment with Lutigest tell your doctor if you have had or have any of the following health problems:
There is no relevant use of Lutigest in children.
Tell your doctor if you are using, have recently used or might use any other medicines.
Some medicines may interact with vaginal progesterone tablets. For example, carbamazepine, rifampin as well as St. John’s wort-containing herbal products may decrease the effectiveness, whereas products containing ketoconazole and vaginal antifungal creams may alter the actions of progesterone.
Lutigest can be used during the first trimester of pregnancy for women who need extra progesterone while undergoing treatment in an Assisted Reproductive Technology (ART) programme.
The risks of congenital (conditions present at birth) anomalies, including genital abnormalities in male or female infants, from exposure to exogenous progesterone during pregnancy have not been fully established.
This medicine should not be used during breast feeding.
Lutigest has minor or moderate influence on the ability to drive and use machines. It may cause drowsiness and/or dizziness; therefore caution is advised in drivers and users of machines.
Always use this medicine exactly as your doctor has told you. You should check with your doctor if you are not sure.
The usual dose is 100 mg placed directly into your vagina three times daily starting on the day of egg retrieval. The administration of Lutigest should be continued for 30 days if pregnancy has been confirmed.
Lutigest is to be placed directly into your vagina by using the applicator provided.
1. Remove one blister from the strip by tearing along the perforations.
2. To remove the foil seal on the back of the blister, start in the corner of the blister pack that has a printed arrow
3. Unwrap the applicator.
4. Put one tablet in the space provided at the end of the applicator. The tablet should fit securely and not fall out.
5. The applicator with the tablet may be inserted into the vagina while you are standing, sitting, or when lying on your back with your knees bent. Gently insert the thin end of the applicator well into the vagina.
6. Push the plunger to release the tablet.
Remove the applicator and rinse it thoroughly in warm running water, wipe dry with a soft tissue and keep the applicator for subsequent use.
Please consult your doctor or pharmacist if you have used more Lutigest than your doctor has told you.
Take the dose as soon as you remember and then carry on as before. Do not take a double dose to make up for a forgotten dose.
Please consult your doctor or pharmacist for advice if you intend to stop or have stopped using Lutigest. Abrupt discontinuation of progesterone dosing may cause increased anxiety, moodiness, and increased sensibility to seizures.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The most common side effects are headache, vaginal disorders and uterine cramping.
The following common side effects affect between 1 and 10 of every 100 patients treated:
The following uncommon side effects affect between 1 and 10 of every 1000 patients treated:
The following side effects have been seen after the product was marketed. Frequency is not known (cannot be estimated from the available data):
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme, website: www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.
Store in the original container in order to protect from light.
This medicinal product does not require any special temperature storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
The active substance is progesterone.
Each vaginal tablet contains 100 mg progesterone.
The other ingredients are:
This medicine is a vaginal tablet. It is a white to off-white convex and oblong tablets debossed with “FPI” on one side and “100” on the other side.
Pack sizes: 21 or 90 vaginal tablets, supplied with one polyethylene vaginal applicator. Not all pack sizes may be marketed.
PL 03194/0103
This medicinal product is authorised in the Member States of the EEA under the following names:
Bulgaria, Czech Republic, Denmark, Finland, Germany, Greece, Hungary, Iceland, Ireland, the Netherlands, Norway, Poland, Slovak Republic, Spain and Sweden: Lutinus
Portugal: Luferti
Romania: Lutinus 100 mg, comprimate vaginale
Slovenia: Lutinus 100 mg vaginalne tablete
United Kingdom: Lutigest
This leaflet was last revised in March 2018
Drayton Hall, Church Road, West Drayton, UB7 7PS, UK
+44 (0)844 931 0051
http://www.ferring.co.uk
+44 (0)844 931 0050
0800 111 4125